1 / 4

Venook AP, et al. ASCO 2011. Abstract 3518 (poster presentation).

Validation of a 12-Gene Colon C ancer Recurrence Score ® in Stage II Colon C ancer P atients from CALGB 9581.

zev
Télécharger la présentation

Venook AP, et al. ASCO 2011. Abstract 3518 (poster presentation).

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Validation of a 12-Gene Colon Cancer Recurrence Score®in Stage II Colon Cancer Patients from CALGB 9581 A.P. Venook1, D. Niedzwiecki2, M. Lopatin3, M. Lee3, P. N. Friedman4, W. Frankel5, K. Clark-Langone3, C. Yoshizawa3, C. Millward3, S. Shak3, R. M. Goldberg6, N. N. Mahmoud7, R. L. Schilsky4, M. M. Bertagnolli8 1. University of California, San Francisco, San Francisco, CA; 2. Duke University, Durham, NC; 3. Genomic Health, Redwood City, CA; 4. The University of Chicago, Chicago, IL; 5. The Ohio State University, Columbus, OH; 6. University of North Carolina at Chapel Hill, Chapel Hill, NC; 7. University of Pennsylvania, Philadelphia, PA; 8. Brigham and Women's Hospital, Boston, MA Venook AP, et al. ASCO 2011. Abstract 3518 (poster presentation).

  2. CALGB 9581: A Unique Opportunity to Test the Oncotype DX® Assay in Low/Standard Risk Stage II Colon Cancer • Sampling design with 690 evaluable patients, including 162 recurrence events, representative of 1,672 stage II colon cancer patients from CALGB 9581 • A population where risk discrimination is challenging with conventional clinical and pathologic factors Venook AP, et al. ASCO 2011. Abstract 3518 (poster presentation).

  3. CALGB 9581: Second Successful Prospectively-Designed Confirmation Study RS, Recurrence Score® Venook AP, et al. ASCO 2011. Abstract 3518 (poster presentation).

  4. CALGB 9581: Improving the Ability to Discriminate High vs. Low Risk of Recurrence in Standard Risk Stage II Colon Cancer RS, Recurrence Score® Venook AP, et al. ASCO 2011. Abstract 3518 (poster presentation).

More Related